Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2017 | The success of recent sarcoma studies

Breelyn A. Wilky, MD, of the Sylvester Comprehensive Cancer Center, Miami, Fl, discusses the success of some of the recent trials in sarcoma research. She talks about 2 studies using checkpoint inhibitors which are now in expansion phases, due to successful initial results, to help even more patients gain access to the treatments. These studies look at the combination of ipilimumab and nivolumab (NCT02500797) and the other, pembrolizumab and SARC 028 (NCT02301039), the pivotal study for monotherapy for sarcoma patients. Furthermore, Dr Wilky talks about another more recent trial she is involved in, with axitinib and pembrolizumab (NCT02636725). She explains that recruitment for this trial has been completed and preliminary data is expected in November. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.